Pfizer's fortunes overshadow first-quarter dealmaking
Aside from Seagen, small takeouts dominate the first quarter.
Conditions are ripe for reverse mergers
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
The slow death of the medtech Spac deal
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Takeout premiums hold up, but that’s not the whole story
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
Nektar and Puretech make strange bedfellows
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.